Company registration number 09644619 (England and Wales)
SSP HEALTH GPMS LTD
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED
30 MARCH 2025
30 March 2025
SSP HEALTH GPMS LTD
COMPANY INFORMATION
Director
Dr S Pitalia
Company number
09644619
Registered office
3rd Floor Waterside House
Waterside Drive
Wigan
WN3 5AZ
Auditor
AMS Audit Limited
1 Hardman Street
Spinningfields
Manchester
M3 3HF
SSP HEALTH GPMS LTD
CONTENTS
Page
Strategic report
1
Director's report
2 - 3
Independent auditor's report
4 - 6
Statement of comprehensive income
7
Balance sheet
8
Statement of changes in equity
9
Statement of cash flows
10
Notes to the financial statements
11 - 20
SSP HEALTH GPMS LTD
STRATEGIC REPORT
FOR THE YEAR ENDED 30 MARCH 2025
- 1 -
The director presents the strategic report for the year ended 30 March 2025.true
Review of the business
The company is an established provider of NHS services throughout the North West of England with a reputation for delivering a first class service.
The company has invested in the growth and infrastructure of the business during the year in order to support future performance and the directors are satisfied with the results of the entity.
Company turnover for the year was £14,345,324 (2024: £12,523,635) with a profit/(loss) before tax of £170,666 (2024: £175,331)
Principal risks and uncertainties
The company uses various financial instruments including cash, trade debtors and trade creditors that arise directly from its operations. The main purpose of this is to finance the company operations.
The main risks arising from the company’s financial instruments are market risk, liquidity risk, interest rate risk and credit risk. The directors review and agree policies for managing each of these risks and they are summarised below:-
Market Risk
Market risk encompasses three types of risk being currency risk, fair value interest rate risk and price risk. The company’s policies for managing fair value interest rate risk are considered along with those for managing cash flow interest rate risk and are set out in the subsection entitled “Interest Rate Risk” below. The company is not currently exposed to price risk or currency risk.
Liquidity Risk
The company seeks to manage financial risk by ensuring sufficient liquidity is available to meet foreseeable needs to invest cash assets safely and profitably. Short term flexibility is achieved by overdraft facilities however they are rarely used.
Interest rate risk
The company finances its operations through retained profits and therefore the directors do not consider this to be a risk.
Credit risk
The company's principal financial assets are cash and trade debtors. The credit risk associated with the cash is limited, and the principal credit risk arises therefore from its trade debtors. It's main customer is the NHS, therefore this risk is considered minimal due to them paying promptly after the invoice has been raised.
Key performance indicators
The main financial metrics used by the Director in assessing business performance is turnover, net profit, EBITDA and cash flow. These KPI's are monitored on a monthly basis to ensure the group continues to drive forward and generate healthy profits and cashflow.
Dr S Pitalia
Director
17 November 2025
SSP HEALTH GPMS LTD
DIRECTOR'S REPORT
FOR THE YEAR ENDED 30 MARCH 2025
- 2 -
The director presents her annual report and financial statements for the year ended 30 March 2025.
Principal activities
The principal activity of the company continued to be that of medical services.
Results and dividends
The results for the year are set out on page 7.
No ordinary dividends were paid. The director does not recommend payment of a final dividend.
Director
The director who held office during the year and up to the date of signature of the financial statements was as follows:
Dr S Pitalia
Auditor
AMS Audit Limited were appointed as auditor to the company and in accordance with section 485 of the Companies Act 2006, a resolution proposing that they be re-appointed will be put at a General Meeting.
Statement of director's responsibilities
The director is responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.
Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the director must not approve the financial statements unless she is satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.
In preparing these financial statements, the director is required to:
select suitable accounting policies and then apply them consistently;
make judgements and accounting estimates that are reasonable and prudent; and
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.
The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. She is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Statement of disclosure to auditor
So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.
SSP HEALTH GPMS LTD
DIRECTOR'S REPORT (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
- 3 -
On behalf of the board
Dr S Pitalia
Director
17 November 2025
SSP HEALTH GPMS LTD
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBER OF SSP HEALTH GPMS LTD
- 4 -
Opinion
We have audited the financial statements of SSP Health GPMS Ltd (the 'company') for the year ended 30 March 2025 which comprise the statement of comprehensive income, the balance sheet, the statement of changes in equity, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
In our opinion the financial statements:
give a true and fair view of the state of the company's affairs as at 30 March 2025 and of its profit for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the director's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the director with respect to going concern are described in the relevant sections of this report.
The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The director is responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of our audit:
the information given in the strategic report and the director's report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the strategic report and the director's report have been prepared in accordance with applicable legal requirements.
SSP HEALTH GPMS LTD
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBER OF SSP HEALTH GPMS LTD (CONTINUED)
- 5 -
Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the director's report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:
adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
the financial statements are not in agreement with the accounting records and returns; or
certain disclosures of director's remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit.
Responsibilities of director
As explained more fully in the director's responsibilities statement, the director is responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the director determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the director is responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the director either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.
Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is
detailed below.
We gained an understanding of the legal and regulatory framework applicable to the company and the industry in which it operates, drawing on our broad sector experience, and considered the risk of acts by the company that were contrary to these laws and regulations, including fraud. We focused on laws and regulations that could give rise to a material misstatement in the financial statements, including, but not limited to, the Care Quality Commission (CQC), Companies Act 2006 and equivalent local laws and regulations.
We made enquiries of management with regards to compliance with the above laws and regulations and corroborated any necessary evidence to relevant information, for example, minutes of the board meetings, legal reports provided to the company and correspondence between the company and its solicitors. Audit procedures performed by the engagement team included:
Discussion with management, including consideration of known or suspected instances of noncompliance with laws and regulations and fraud;
Review of financial statement disclosures to underlying supporting documentation;
Challenging assumptions and judgements made by management in their significant accounting estimates;
Our audit procedures were designed to respond to risks of material misstatement in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery, misrepresentations or through collusion. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we are to become aware of it.
SSP HEALTH GPMS LTD
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBER OF SSP HEALTH GPMS LTD (CONTINUED)
- 6 -
A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.
Other matters which we are required to address
This is the first accounting period which we have been appointed as auditors of the company and in consequence the prior year figures for the year ended 30 March 2024 are unaudited.
This report is made solely to the company's member in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's member those matters we are required to state to the member in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's member, for our audit work, for this report, or for the opinions we have formed.
Andrew Davis ACCA CTA MAAT (Senior Statutory Auditor)
For and on behalf of AMS Audit Limited, Statutory Auditor
Chartered Accountants
1 Hardman Street
Spinningfields
Manchester
M3 3HF
17 November 2025
SSP HEALTH GPMS LTD
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 30 MARCH 2025
- 7 -
2025
2024
Notes
£
£
Turnover
3
14,345,324
12,523,635
Cost of sales
(213,122)
(249,406)
Gross profit
14,132,202
12,274,229
Administrative expenses
(13,961,569)
(12,098,898)
Operating profit
4
170,633
175,331
Interest receivable and similar income
7
33
Profit before taxation
170,666
175,331
Tax on profit
8
(42,666)
(43,103)
Profit for the financial year
128,000
132,228
The profit and loss account has been prepared on the basis that all operations are continuing operations.
SSP HEALTH GPMS LTD
BALANCE SHEET
AS AT
30 MARCH 2025
30 March 2025
- 8 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
9
34,909
44,996
Current assets
Debtors
11
3,145,537
2,075,767
Cash at bank and in hand
13,987
11,027
3,159,524
2,086,794
Creditors: amounts falling due within one year
12
(2,306,239)
(1,370,321)
Net current assets
853,285
716,473
Total assets less current liabilities
888,194
761,469
Provisions for liabilities
Deferred tax liability
13
3,045
4,320
(3,045)
(4,320)
Net assets
885,149
757,149
Capital and reserves
Called up share capital
15
100
100
Profit and loss reserves
885,049
757,049
Total equity
885,149
757,149
These financial statements have been prepared in accordance with the provisions relating to medium-sized companies.
The financial statements were approved and signed by the director and authorised for issue on 17 November 2025
Dr S Pitalia
Director
Company registration number 09644619 (England and Wales)
SSP HEALTH GPMS LTD
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 MARCH 2025
- 9 -
Share capital
Profit and loss reserves
Total
£
£
£
Balance at 31 March 2023
100
624,821
624,921
Year ended 30 March 2024:
Profit and total comprehensive income
-
132,228
132,228
Balance at 30 March 2024
100
757,049
757,149
Year ended 30 March 2025:
Profit and total comprehensive income
-
128,000
128,000
Balance at 30 March 2025
100
885,049
885,149
SSP HEALTH GPMS LTD
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 MARCH 2025
- 10 -
2025
2024
Notes
£
£
£
£
Cash flows from operating activities
Cash generated from operations
19
70,170
23,043
Income taxes paid
(62,688)
(18,869)
Net cash inflow from operating activities
7,482
4,174
Investing activities
Purchase of tangible fixed assets
(4,555)
(14,285)
Repayment of loans
100
Interest received
33
Net cash used in investing activities
(4,522)
(14,185)
Net increase/(decrease) in cash and cash equivalents
2,960
(10,011)
Cash and cash equivalents at beginning of year
11,027
21,038
Cash and cash equivalents at end of year
13,987
11,027
SSP HEALTH GPMS LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 MARCH 2025
- 11 -
1
Accounting policies
Company information
SSP Health GPMS Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 3rd Floor Waterside House, Waterside Drive, Wigan, WN3 5AZ.
1.1
Basis of preparation
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
1.2
Going concern
Atruet the time of approving the financial statements, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the director continues to adopt the going concern basis of accounting in preparing the financial statements.
1.3
Revenue
Turnover is recognised at the fair value of the consideration received or receivable for services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates. Sales, interest and dividend income is recognised on an accruals basis.
When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.
1.4
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Plant and machinery
25% straight line
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
1.5
Impairment of fixed assets
At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.
SSP HEALTH GPMS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
1
Accounting policies
(Continued)
- 12 -
Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.
If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.
Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.
1.6
Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
1.7
Financial instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
Other financial assets
Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.
SSP HEALTH GPMS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
1
Accounting policies
(Continued)
- 13 -
Impairment of financial assets
Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.
Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.
If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.
Derecognition of financial assets
Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
Other financial liabilities
Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.
Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value through profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.
SSP HEALTH GPMS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
1
Accounting policies
(Continued)
- 14 -
Derecognition of financial liabilities
Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.
1.8
Equity instruments
Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.
1.9
Derivatives
Derivatives are initially recognised at fair value at the date a derivative contract is entered into and are subsequently remeasured to fair value at each reporting end date. The resulting gain or loss is recognised in profit or loss immediately unless the derivative is designated and effective as a hedging instrument, in which event the timing of the recognition in profit or loss depends on the nature of the hedge relationship.
A derivative with a positive fair value is recognised as a financial asset, whereas a derivative with a negative fair value is recognised as a financial liability.
1.10
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
1.11
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
SSP HEALTH GPMS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
1
Accounting policies
(Continued)
- 15 -
1.12
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
1.13
Leases
As lessee
Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.
1.14
Foreign exchange
Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.
2
Judgements and key sources of estimation uncertainty
In the application of the company’s accounting policies, the director is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
There are no significant accounting judgements or items with estimation uncertainty in the current or prior period.
3
Turnover and other revenue
An analysis of the company's turnover is as follows:
2025
2024
£
£
Turnover analysed by class of business
Medical services
14,345,324
12,523,635
2025
2024
£
£
Turnover analysed by geographical market
UK
14,345,324
12,523,635
2025
2024
£
£
Other revenue
Interest income
33
-
SSP HEALTH GPMS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
- 16 -
4
Operating profit
2025
2024
Operating profit for the year is stated after charging:
£
£
Fees payable to the company's auditor for the audit of the company's financial statements
10,000
Depreciation of tangible fixed assets
14,642
206
Operating lease charges
6,141
-
5
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2025
2024
Number
Number
Employees
123
149
Their aggregate remuneration comprised:
2025
2024
£
£
Wages and salaries
9,549,234
10,308,589
Social security costs
359,099
210,033
Pension costs
486,786
170,959
10,395,119
10,689,581
6
Director's remuneration
No remuneration was paid to the director.
7
Interest receivable and similar income
2025
2024
£
£
Interest income
Interest on bank deposits
33
2025
2024
Investment income includes the following:
£
£
Interest on financial assets not measured at fair value through profit or loss
33
SSP HEALTH GPMS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
- 17 -
8
Taxation
2025
2024
£
£
Current tax
UK corporation tax on profits for the current period
43,941
38,783
Deferred tax
Origination and reversal of timing differences
(1,275)
4,320
Total tax charge
42,666
43,103
The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:
2025
2024
£
£
Profit before taxation
170,666
175,331
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (2024: 25.00%)
42,667
43,833
Tax effect of expenses that are not deductible in determining taxable profit
(1)
(730)
Taxation charge for the year
42,666
43,103
9
Tangible fixed assets
Plant and machinery
£
Cost
At 31 March 2024
57,892
Additions
4,555
At 30 March 2025
62,447
Depreciation and impairment
At 31 March 2024
12,896
Depreciation charged in the year
14,642
At 30 March 2025
27,538
Carrying amount
At 30 March 2025
34,909
At 30 March 2024
44,996
SSP HEALTH GPMS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
- 18 -
10
Financial instruments
£
£
Carrying amount of financial assets include:
Debt instruments measured at amortised cost
3,101,506
2,046,547
Carrying amount of financial liabilities include:
Measured at amortised cost
2,205,942
1,256,884
11
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
106,755
(7,571)
Other debtors
2,540,015
1,214,076
Prepayments and accrued income
498,767
869,262
3,145,537
2,075,767
12
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
342,783
252,573
Corporation tax
20,019
38,766
Other taxation and social security
80,278
74,671
Other creditors
673,141
285,971
Accruals and deferred income
1,190,018
718,340
2,306,239
1,370,321
13
Deferred taxation
Deferred tax assets and liabilities are offset where the company has a legally enforceable right to do so. The following is the analysis of the deferred tax balances (after offset) for financial reporting purposes:
Liabilities
Liabilities
2025
2024
Balances:
£
£
Accelerated capital allowances
3,045
4,320
2025
Movements in the year:
£
Liability at 31 March 2024
4,320
Credit to profit or loss
(1,275)
Liability at 30 March 2025
3,045
SSP HEALTH GPMS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
13
Deferred taxation
(Continued)
- 19 -
The deferred tax liability set out above is expected to reverse in the future and relates to accelerated capital allowances that are expected to mature within the same period.
14
Retirement benefit schemes
2025
2024
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
486,786
170,959
The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund.
15
Share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary of £1 each
100
100
100
100
16
Financial commitments, guarantees and contingent liabilities
Bank loans and overdrafts of the company are secured by a fixed and floating charge over all property and assets of the company in favour of Santander UK PLC.
In addition, there is an Omnibus Guarantee and set off arrangement which includes SSP Health GPMS Ltd, SSP Health Holding Ltd, SSP Health Medical Services Ltd and SSP Health Primary Care Limited, together which such other security as the Bank may from time to time hold in respect of the debts and liabilities of any guarantor to the bank.
17
Related party transactions
Transactions with related parties
During the year the company entered into the following transactions with related parties:
Purchases
Purchases
2025
2024
£
£
Companies under common control
1,827,011
4,601
2025
2024
Amounts due to related parties
£
£
Companies under common control
5,601
-
The amounts outstanding at the year end are unsecured, interest free and repayable on demand.
SSP HEALTH GPMS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
17
Related party transactions
(Continued)
- 20 -
The following amounts were outstanding at the reporting end date:
2025
2024
Amounts due from related parties
£
£
Companies under common control
2,887,833
1,678,016
The amounts outstanding at the year end are unsecured, interest free and repayable on demand.
18
Ultimate controlling party
By virtue of ownership of the entire issued share capital, Dr S Pitalia controls the company.
19
Cash generated from operations
2025
2024
£
£
Profit after taxation
128,000
132,228
Adjustments for:
Taxation charged
42,666
43,103
Investment income
(33)
Depreciation and impairment of tangible fixed assets
14,642
206
Pension scheme non-cash movement
-
(30,963)
Movements in working capital:
Increase in debtors
(1,069,770)
(349,622)
Increase in creditors
954,665
228,091
Cash generated from operations
70,170
23,043
20
Analysis of changes in net funds
31 March 2024
Cash flows
30 March 2025
£
£
£
Cash at bank and in hand
11,027
2,960
13,987
2025-03-302024-03-31falsefalsefalseCCH SoftwareCCH Accounts Production 2025.300Dr S Pitalia096446192024-03-312025-03-30096446192025-03-3009644619bus:Director12024-03-312025-03-3009644619bus:RegisteredOffice2024-03-312025-03-30096446192023-03-312024-03-3009644619dpl:Item12024-03-312025-03-3009644619dpl:Item12023-03-312024-03-3009644619core:RetainedEarningsAccumulatedLosses2023-03-312024-03-3009644619core:RetainedEarningsAccumulatedLosses2024-03-312025-03-30096446192024-03-3009644619core:PlantMachinery2025-03-3009644619core:PlantMachinery2024-03-3009644619core:CurrentFinancialInstruments2025-03-3009644619core:CurrentFinancialInstruments2024-03-3009644619core:ShareCapital2025-03-3009644619core:ShareCapital2024-03-3009644619core:RetainedEarningsAccumulatedLosses2025-03-3009644619core:RetainedEarningsAccumulatedLosses2024-03-3009644619core:ShareCapital2023-03-3009644619core:RetainedEarningsAccumulatedLosses2023-03-30096446192023-03-3009644619core:ShareCapitalOrdinaryShareClass12025-03-3009644619core:ShareCapitalOrdinaryShareClass12024-03-30096446192024-03-3009644619core:PlantMachinery2024-03-312025-03-3009644619core:UKTax2024-03-312025-03-3009644619core:UKTax2023-03-312024-03-3009644619core:PlantMachinery2024-03-3009644619bus:OrdinaryShareClass12024-03-312025-03-3009644619bus:OrdinaryShareClass12025-03-3009644619bus:OrdinaryShareClass12024-03-3009644619bus:PrivateLimitedCompanyLtd2024-03-312025-03-3009644619bus:FRS1022024-03-312025-03-3009644619bus:Audited2024-03-312025-03-3009644619bus:FullAccounts2024-03-312025-03-30xbrli:purexbrli:sharesiso4217:GBP